Navamedic: Positioned for Growth in Promising Healthcare Segments - Analyst Group

Navamedic ASA (”Navamedic” or ”the Company”) is a Nordic pharmaceutical company offering a diversified portfolio of prescription drugs, consumer health products, and hospital solutions in the Nordic region, the Baltics, and the Benelux region. Following a strategic shift in 2019, transitioning from a distribution-based model to owning brands, Navamedic has enhanced profitability and scalability. The Company’s licensing platform, enabling control over product portfolios and facilitating market expansion, positions Navamedic for sustained growth going forward. Navamedic is estimated to reach an EBIT of NOK 71.1m in 2026 and based on an applied EV/EBIT target multiple of 10.4x, a potential price per share of NOK 37.5 is implied in a Base scenario.